News >

Adjuvant Therapy Transforms Treatment in Advanced Melanoma

Caroline Seymour
Published: Thursday, Jan 16, 2020

Jeffrey Weber, MD, PhD

Jeffrey Weber, MD, PhD
Adjuvant therapy has revolutionized the field of melanoma by treating patients with resected disease with active regimens that have historically been used in the metastatic setting, said Jeffrey S. Weber, MD, PhD.

In 2014, the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) was granted accelerated approval for use in patients with unresectable or metastatic melanoma who harbor a BRAF mutation. Subsequently, the combination was evaluated as an adjuvant therapy in the phase III COMBI-AD trial in patients with resected stage III, BRAF-mutant disease.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication